Estrogens, Total

What Estrogens, Total actually measures — the analyte, and the assay

The analyte is a sum, and that is the whole problem. ‘Total estrogens’ is not a molecule. It is estrone (E1, 270 Da), estradiol (E2, 272 Da) and estriol (E3, 288 Da) added together and printed as one figure — and on some platforms the sulfated and glucuronidated conjugates as well, depending on whether the laboratory hydrolyzes the specimen before it measures anything. Three molecules with three different receptor affinities, three different tissues of origin and three completely different clinical meanings, resolved into a single number.

The method is a broad antibody, deliberately. On every other steroid assay, cross-reactivity is the defect; on a total estrogens immunoassay it is the design specification. The antibody is chosen to bind the shared steroid nucleus rather than to discriminate between estrone and estradiol, which means the weighting it applies to each fraction is a property of that antibody and not of your circulation. Two laboratories can report the same serum differently not because one is wrong but because their antibodies count estrone differently Ghazal 2022 Lorde 2023.

Do the arithmetic on who dominates the sum. In 1,207 healthy postmenopausal women aged 41 to 92, estradiol sat at 9–12 pg/mL across age bands while estrone sat at 33–35 pg/mL Stanczyk 2022. Estrone is therefore roughly three times estradiol in that population, so about three-quarters of a postmenopausal ‘total estrogens’ result is a hormone with a fraction of estradiol's receptor potency. The number is real. What most people think it measures is not what is inside it.

What to ask for instead. The Endocrine Society's position statement on estradiol measurement is explicit that assay performance is adequate for the high concentrations of infertility management and poor at the low concentrations everything else is asked about Rosner 2013, and a 2023 joint laboratory and endocrinology position statement says the same thing about sex steroids generally: mass spectrometry is what international societies have recommended for a decade and it belongs in routine health systems Casals 2023. The orderable version of that advice is estrone and estradiol reported separately by LC-MS/MS, not one antibody's opinion of their sum.

Estrogens, Total: what changes the blood, and what only changes the reading

What changes the estrogen in your blood — largest term first:

1. Ovarian activity, or its end. Before menopause the ovary makes estradiol directly and the total tracks the cycle. After it, the ovarian term is gone and what remains is peripheral aromatization, which is why the composition of the number flips from estradiol-dominant to estrone-dominant Stanczyk 2022.
2. Body fat, through aromatase. In the Ghana Breast Health Study, postmenopausal women with a BMI of 30 kg/m² or above had unconjugated estrone of 78.90 pg/mL against 50.89 pg/mL in women at 18.5–24.9 kg/m², and unconjugated estradiol of 27.83 pg/mL against 13.26 pg/mL, both at p < 0.0001 Geczik 2022. Note what that pair of numbers says: estrone stays the bigger fraction at every body size, and adiposity raises the total mostly by raising the fraction nobody is thinking about.
3. Oral estrogen. An oral dose goes through the liver before it goes anywhere else, and hepatic 17β-hydroxysteroid dehydrogenase converts a large share of it to estrone. Total estrogens therefore rises far more than estradiol does on oral therapy, and far less disproportionately on a transdermal one.
4. Aromatase inhibitors lower all three fractions at once, which is why a total is a poor way to titrate one.
5. Alcohol and hepatic clearance. Estrogens are cleared by conjugation in the liver; impaired clearance raises the pool without anything having been made.
6. hCG or gonadotropin exposure in men, which drives testicular aromatase substrate and lifts estradiol first.

What changes only the reading:

1. Whether the sample was hydrolyzed. Conjugated estrogens outnumber the free ones by an order of magnitude, so an assay that counts them and one that does not are not measuring comparable quantities under the same name.
2. The antibody's fraction weighting, which is the design feature above and cannot be corrected by the reader Ghazal 2022.
3. Biotin on any streptavidin-capture platform, and heterophile antibodies, which bridge capture and detection antibodies with no steroid involved at all Braunstein 2022.
4. Which reference interval the laboratory printed beside it, since between-assay differences and between-interval differences compound into a diagnosis that changes with the letterhead Lorde 2023.

Reference interval or decision threshold — which kind of number Estrogens, Total is

A reference interval — and a reference interval for a sum, which is a weaker claim than it looks. The 40–115 pg/mL quoted for men is the central 95% of whoever that laboratory measured on that laboratory's platform. It is not tied to any outcome. No guideline body publishes a total estrogens concentration above which anything happens to a person.

Two laboratories disagree for two independent reasons that multiply rather than cancel: their antibodies weight estrone and estradiol differently, and their reference populations differ. A 2023 review of exactly this problem — variation between assays and between reference intervals in endocrine diagnosis — treats the combination as a routine driver of misdiagnosis rather than an edge case Lorde 2023.

There is no decision threshold for this marker anywhere. That is worth stating flatly, because estradiol has a formal measurement position statement behind it Rosner 2013 and total estrogens has nothing comparable. A number with a printed range and no outcome anchor invites the reader to treat the edge of the interval as a treatment trigger, and here the interval cannot bear that weight: two people with an identical total of 100 pg/mL — one at 90 estrone and 10 estradiol, the other at 40 and 60 — need opposite advice.

How you would know your Estrogens, Total was wrong — and when to redraw

Redraw the parts, not the sum. Estrone and estradiol both have circulating half-lives measured in hours, so the retest interval is set by whatever you changed, not by the molecule: 8–12 weeks after a change in body composition, 4–6 weeks after a change in hormone route or dose. In a cycling woman the draw must repeat the same cycle day, conventionally days 2–5, or the second value is a measurement of the calendar.

What would have to change for the second number to mean anything. A real shift in estrogen exposure drags its neighbors with it, and those neighbors are the confirmation:

• Estradiol by the sensitive LC-MS/MS assay should move in the same direction and by a similar proportion. If the total moved and this did not, the change was in estrone or in the antibody.
• SHBG, which estrogen raises, should track upward with a genuine rise; a total that climbs with SHBG flat is more likely analytical.
• Total testosterone and free testosterone, because they are the aromatase substrate — a rise driven by adiposity should show a falling or static androgen alongside a rising estrogen.
• LH/FSH in a woman, to establish whether the ovarian term is still contributing at all.

The falsifying result is simple to state: total estrogens moving on its own, with sensitive estradiol, SHBG and total testosterone all unchanged, is an assay result and not a physiological one. Confirm on a different platform before acting, exactly as you would with any immunoassay-only finding Alvarez-Payares 2021.

What Estrogens, Total cannot tell you

It cannot tell you which estrogen you have. That single sentence is most of what a reader needs, and it is the thing the test is most often bought to answer.

It cannot be used to decide on an aromatase inhibitor in a man. The decision needs a fraction, measured well, at a concentration immunoassays are known to handle badly Rosner 2013; and the testosterone-to-estradiol ratio people reach for instead has no established optimum either, with the frequently quoted 10–30 band described in its own review as unsettled because the measurements are not standardized Swislocki 2024.

It cannot establish menopausal status, which FSH and a menstrual history do better and cheaper.

Estriol contributes essentially nothing outside pregnancy. It is a placental product; in a non-pregnant adult it is a rounding error inside the total, so a third of the test's name is doing no work.

The wrong inference readers reliably draw is ‘my estrogen is high, so I need to lower my estrogen’. In a man with high body fat the arithmetic says most of that elevation is estrone Geczik 2022 — a weak agonist — and the intervention that actually lowers it is the fat, not a drug aimed at a fraction nobody measured.

Sources read for these sections

• Rosner W, et al. Challenges to the measurement of estradiol: an endocrine society position statement. Journal of Clinical Endocrinology and Metabolism 2013 · PMID 23463657
• Stanczyk FZ, et al. Concentrations of endogenous sex steroid hormones and SHBG in healthy postmenopausal women. Journal of Steroid Biochemistry and Molecular Biology 2022 · PMID 35182725
• Geczik AM, et al. Measured body size and serum estrogen metabolism in postmenopausal women: the Ghana Breast Health Study. Breast Cancer Research 2022 · PMID 35081987
• Casals G, et al. Recommendations for the measurement of sexual steroids in clinical practice. A position statement of SEQCML/SEEN/SEEP. Advances in Laboratory Medicine 2023 · PMID 37359897
• Lorde N, et al. Impact of Variation between Assays and Reference Intervals in the Diagnosis of Endocrine Disorders. Diagnostics (Basel) 2023 · PMID 37998589
• Ghazal K, et al. Hormone Immunoassay Interference: A 2021 Update. Annals of Laboratory Medicine 2022 · PMID 34374345